TorHoerman Law Launches New Website To Help Those Experiencing Symptoms of Antibiotic Toxicity

Nov 16, 2015, 15:30 ET from TorHoerman Law

EDWARDSVILLE, Ill., Nov. 16, 2015 /PRNewswire/ -- TorHoerman Law announces the launch of a new website - –to assist in warning the public of the potential link between popular antibiotics and a serious disability called fluoroquinolones-associated disability (FQAD).  Last week, an FDA advisory panel recommended the FDA take action to warn the public of the risk of FQAD.

TorHoerman Law is currently speaking to previously healthy individuals that believe their use of the popular antibiotics- fluoroquinolones (such as Cipro, Avelox and Levaquin) led to a substantial disruption in their ability to conduct normal life functions.  An FDA advisory committee is referring to these "constellation of symptoms" that are triggered throughout the body as FQAD and is now recommending that the FDA warn the public of this risk.

TorHoerman Law is launching with the primary goal of providing critical  information  to the potentially effected individual Secondarily, we plan to gather information to determine whether the manufacturers of these antibiotics should be held accountable for the disabling side effects and symptoms of FQAD.   

TorHoerman Law is a recognized leader in products liability cases, recently serving as co-lead counsel for the plaintiffs on the Actos bladder cancer cases that settled for $2.4 billion (In Re:Actos Related Cases, Circuit Court of Cook County, Illinois) and the Pradaxa bleeding cases that settled for $650 million (In Re:Pradaxa, U.S. District Court for the Southern District of Illinois).  TorHoerman Law believes in justice for people injured when safety takes the backseat to profits. 

According to Tor Hoerman, "studies now clearly indicate that previously healthy individuals with no prior medical history can develop life-altering symptoms while on FQs - even after stopping the course of medication.  We built this website to provide information to those severely affected by these drugs.  We are waiting to see whether the FDA takes regulatory action, and, if they do, whether it is in the best interest of those impacted to pursue litigation.  Our goal is to help people make the most informed decision before getting into litigation.  These decisions should not be made lightly either by the client or the lawyer because if litigation is what we choose, we will pursue with everything we have."

Logo -



SOURCE TorHoerman Law